entertainment -WSS

entertainment

author：leisure time 2025-09-29 22:51:23 - browse：72516

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： New rules on organ donation and transplantation 'will bring chaos'

WSS

FDA panel signals lack of confidence in Amgen cancer drug data

7 of the most gruesome medical devices in history

The future of health care in the House

How artificial intelligence is being used to detect, treat cancer

A double vaccine crisis is endangering millions of children

CDC backtracks, saying fully vaccinated people can go maskless indoors

hotspot

entertainment

explore

Jerome Adams on the need for new antivirals for Covid

The future of health care in the House

New air purifier tech could be key to improving indoor air quality

Chan Zuckerberg Biohub Chicago to focus on inflammation

The high cost of giving birth even with insurance

White House launches permanent pandemic office

As demand for Covid shots wanes, Moderna seeks its next success

7 of the most gruesome medical devices in history

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

focus

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

A double vaccine crisis is endangering millions of children

3 questions for the future of Biden's cancer moonshot

AbbVie dramatically boosts its spending on lobbying

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Providers still hesitate to prescribe buprenorphine, study finds

hotspot

hotspot

Wikipedia

Wikipedia